Welcome

Please select your view

pathology-focus-dec-mirette-banner_1800x424px2jpg

Pharmacogenetic Testing

Pharmacogenetics (PGx), an important part of precision medicine, is the study of how genetic variability influences drug treatment outcomes. Recommended by Guidelines, many medications currently prescribed have pharmacogenetic data to support appropriate dosing or selection. Like all diagnostic tests, pharmacotherapeutic genotyping is one of multiple pieces of information that clinicians should consider when making their therapeutic choice for each patient.

Clinical Labs offers a comprehensive range of pharmacogenetic testing in order to provide Clinicians and healthcare providers with important information to help decide on the most appropriate treatment for each individual, particularly in areas such as mental health, pain management, cardiology and oncology.

Download Pharmacogenetic Testing Brochure


"The field of pharmacogenetics
involves using a patient’s genetic makeup in combination with other clinical information to create a personalised medication regimen with greater efficacy and safety for the individual patient."




Pharmacogenetic (PGx) test list at Australian Clinical Labs


Our comprehensive pharmacogenetic tests can detect polymorphisms in genes coding for drug metabolising enzymes that predispose individuals to metabolising drugs inadequately.

Gene panels offered:
Cytochrome P450 Comprehensive Gene Panel including*:
CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP1A2, SLCO1B1 and VKORC1

Single gene test:
TPMT (Medicare rebate)
DPYD
UGT1A1

*Please note that the panel Cytochrome P450 Genes can be ordered separately or together (CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP1A2, SLCO1B1 and VKORC1).

For a full listing of genes tested and drugs metabolised, download the below brochure. 


Download Pharmacogenetic Testing Brochure

When to order: Before commencing therapy, with adverse reaction or resistance.

How to order:
Fill out our routine Clinical Labs testing request form, list the gene required or group of genes and prescribed medications if available.

Turanaround time: Results will be available after 7-10 business days from the sample receipt date.

Specimen required: 2x EDTA blood samples.

Report: You will receive a comprehensive report that will indicate the genotype and the predicted phenotypes, such as the metaboliser status along with potential drug-gene interaction and guidelines’ recommendations.

Test cost: Apart from the TPMT gene, CYP450 Variants are non-Medicare (an out-of-pocket fee applies).

 

Expert Chemical Pathologist

National Director of Molecular Genetics Australian Clinical Labs, Associate Professor Mirette Saad. 

Assoc. Prof. Mirette Saad

MBBS (HONS), MD (HONS), MAACB, FRCPA, PHD
Lab: Clayton
Speciality: Chemical Pathology
Areas of interest: Molecular genetics, precision medicine, cancer genetics, antenatal screening, NIPT, endocrine,
fertility testing and research, medical teaching

Phone: (03) 9538 6777
Email: mirette.saad@clinicallabs.com.au

Associate Professor Mirette Saad is a Consultant Chemical Pathologist and the National Director of Molecular Genetics at Australian Clinical Labs. At Clinical Labs, A/Prof Mirette Saad leads the Molecular Genetic testing for non-invasive prenatal testing (NIPT), antenatal screening, personalised drug therapy and cancer. She is a Chair of the RCPA Chemical Pathology Advisory Committee, Member of the RCPA Genetic Advisory Committee, AACB and a Chair of the Precision Medicine Services at Australian Clinical Labs.